Pieter R. Cullis Patents & Innovation Profile — PatSnap Eureka
Pieter R. Cullis: Patent Portfolio & Innovation Analysis
Pieter R. Cullis is a Professor in the Department of Biochemistry and Molecular Biology at the University of British Columbia and one of the world's foremost scientists in lipid nanoparticle (LNP) drug delivery, holding 770 patent filings spanning ionizable lipid chemistry, siRNA and mRNA encapsulation, microfluidic LNP manufacturing, and hepatic gene silencing. His foundational research underpins Onpattro — the first FDA-approved LNP-based siRNA therapeutic — and the mRNA delivery platforms used in both the Moderna and Pfizer-BioNTech COVID-19 vaccines.
Most Cited Research Works
The 2019 Onpattro paper leads with 1,319 citations — the highest in this dataset — reflecting the clinical and scientific impact of Cullis's LNP translation work.
Core Areas of Innovation
Pieter R. Cullis's 770-patent portfolio spans five interconnected technology domains, from foundational ionizable lipid chemistry through to clinical-stage mRNA delivery and personalised nanomedicine manufacturing.
Ionizable Lipid Design & LNP Formulation
Core domainPatents in this domain cover the design, synthesis, and optimisation of ionizable cationic lipids — the critical component that enables LNPs to encapsulate nucleic acids at low pH and release them in the endosome. The identification of an optimal pKa window of 6.2–6.5 for in vivo gene silencing efficiency is a cornerstone of this body of work.
- Ionizable cationic lipid compositions for nucleic acid delivery
- LNP formulations with optimised pKa for hepatic gene silencing
- Cationic lipid-nucleic acid particle systems
siRNA & mRNA Encapsulation and Delivery
Core domainThis domain encompasses patents on the encapsulation of siRNA and mRNA payloads within LNP systems, including methods for achieving high encapsulation efficiency, controlling release kinetics, and enabling intracellular delivery of functional nucleic acids. It directly underpins the Onpattro siRNA therapeutic and mRNA vaccine delivery platforms.
- Methods for siRNA encapsulation in lipid nanoparticles
- mRNA-LNP formulations for vaccine and therapeutic applications
- PEG-lipid systems for extended circulation and nucleic acid delivery
Microfluidic LNP Manufacturing
Core domainPatents here cover microfluidic rapid-mixing technologies for the scalable, reproducible synthesis of lipid nanoparticles with controlled size and nucleic acid encapsulation efficiency. This manufacturing science is now standard in both research and GMP production of LNP-based therapeutics and vaccines globally.
- Microfluidic devices and methods for LNP synthesis
- Scalable rapid-mixing systems for nucleic acid-LNP production
- Size-controlled LNP manufacturing via microfluidic channels
Hepatic Gene Silencing & Targeting
Core domainPatents in this domain address the specific targeting of LNPs to hepatocytes for gene silencing applications in metabolic and genetic diseases. This includes liver-targeted siRNA delivery systems, apolipoprotein-mediated uptake mechanisms, and formulations designed for hepatic accumulation following systemic administration.
- LNP systems for hepatic gene silencing via systemic delivery
- Glucagon receptor siRNA formulations for metabolic disease
- Apolipoprotein-mediated hepatocyte targeting of nucleic acid LNPs
Extrahepatic & Organ-Selective Delivery
Emerging domainAn emerging frontier in Cullis's portfolio, this domain covers LNP systems engineered for delivery to tissues beyond the liver — including lung, T lymphocytes, neurons, and tumour microenvironments. Nebulization-stable LNP formulations, anionic LNP systems, and organ-selective targeting strategies are key themes.
- Nebulization-stable LNP formulations for pulmonary mRNA delivery
- T lymphocyte-targeted LNP systems for immunotherapy
- Anionic LNP systems for extrahepatic nucleic acid delivery
PEG-Lipid Systems & Surface Engineering
Core domainPatents in this area cover polyethylene glycol (PEG) lipid conjugates used to stabilise LNPs, extend circulation half-life, and modulate immune recognition. The influence of PEG-lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA LNPs is a central theme, with direct implications for clinical dosing and safety profiles.
- PEG-lipid conjugates for LNP steric stabilisation
- Cleavable PEG-lipid systems for triggered nucleic acid release
- PEG density optimisation for pharmacokinetic control
Research Literature by Pieter R. Cullis
79 papers indexed · spanning early-2000s foundational biophysics through to 2025 publications on next-generation LNP design, extrahepatic delivery, and personalised nanomedicine manufacturing.
Top 5 Most Cited Papers — Citation Counts
The five most highly cited works in this dataset account for over 3,572 citations combined. The 2019 Onpattro paper alone accounts for 1,319 citations, reflecting the landmark clinical and regulatory significance of LNP-mediated siRNA delivery.
| Title | Year | Citations | Key Affiliations | Link |
|---|---|---|---|---|
| The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs | 2019 | 1,319 ↑ | UBC, Alnylam Pharmaceuticals, Acuitas Therapeutics | View → |
| Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo | 2012 | 997 ↑ | UBC, AlCana Technologies, Alnylam Pharmaceuticals | View → |
| On the Formation and Morphology of Lipid Nanoparticles Containing Ionizable Cationic Lipids and siRNA | 2018 | 525 ↑ | UBC, Simon Fraser University, Integrated Nanotherapeutics, UMC Utrecht | View → |
| Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics | 2019 | 385 ↑ | UMC Utrecht, UBC, Eindhoven University of Technology, Integrated Nanotherapeutics | View → |
| Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA LNPs | 2013 | 346 ↑ | UBC, Acuitas Therapeutics, Alnylam Pharmaceuticals | View → |
🔬 Ionizable Lipid Design & LNP Structural Biology
A substantial portion of Cullis's literature addresses the biophysical principles underlying LNP function. The critical finding that ionizable cationic lipids with a pKa of 6.2–6.5 maximise in vivo gene silencing efficiency — cited nearly 1,000 times — is a cornerstone reference in every subsequent ionizable lipid design programme across the industry.
⚙️ Microfluidic Manufacturing & Scalable LNP Production
Cullis was a central figure in establishing microfluidic rapid-mixing as the preferred scalable method for LNP synthesis. Publications from Precision NanoSystems — co-founded by members of the Cullis group — extend this into modular LNP platforms accommodating different RNA payloads. A 2025 paper on the NANOSPRESSO project signals a forward-looking direction toward decentralised, personalised nanomedicine production.
🏥 Clinical Translation — From Hepatic to Extrahepatic Delivery
The most directly translational strand traces the path from laboratory LNP systems to clinical products. Applications span hepatic gene silencing in metabolic disease, targeted siRNA in prostate cancer, neuronal gene silencing, T lymphocyte targeting, and mRNA delivery to all major organs in large animal models — with 2025 publications confirming active extrahepatic delivery research.
Pieter R. Cullis's Institutional Collaborators
Key Institutional Partners
Collaboration Highlights
Cullis's collaboration network spans both academic and commercial institutions, reflecting the translational nature of his research. Alnylam Pharmaceuticals — the developer of Onpattro — appears as a co-author in three of the five most cited papers, while Acuitas Therapeutics (which licensed LNP technology for COVID-19 mRNA vaccines) features in two. The network extends internationally to UMC Utrecht and Eindhoven University of Technology, and across multiple UBC spin-out companies including Integrated Nanotherapeutics, AlCana Technologies, and Precision NanoSystems.
- Alnylam Pharmaceuticals 3 top-cited papers
- Acuitas Therapeutics 2 top-cited papers
- Integrated Nanotherapeutics 2 top-cited papers
- UMC Utrecht 2 top-cited papers
- AlCana Technologies 1 top-cited paper
Pieter R. Cullis's Patent Assignee Ecosystem
Cullis's 770-patent portfolio is distributed across a network of academic institutions and biotechnology companies in the Vancouver life sciences ecosystem and beyond, creating a complex multi-party IP environment for any organisation working in LNP therapeutics.
Key Patent-Holding Organisations
IP Ecosystem Overview
The commercialisation of Cullis's research through multiple spin-out companies creates a complex multi-party patent landscape. Key platform technologies appear to be held across Acuitas Therapeutics (which has licensed LNP technology to multiple vaccine and therapeutic developers, including for COVID-19 mRNA vaccines), Arbutus Biopharma (whose LNP patent estate has been the subject of significant inter partes review proceedings), and NanoVation Therapeutics.
Why Pieter R. Cullis's Portfolio Matters
Strategic implications for patent attorneys, in-house IP teams, and R&D strategists working in RNA therapeutics, LNP delivery, and mRNA vaccine development.
FTO Considerations
With 770 filings associated with UBC, Acuitas Therapeutics, Arbutus Biopharma, Precision NanoSystems, Integrated Nanotherapeutics, and NanoVation Therapeutics, virtually any programme involving ionizable lipid LNP formulations, microfluidic LNP manufacturing, siRNA or mRNA encapsulation, PEG-lipid systems, or hepatic nucleic acid delivery will require careful FTO analysis against this body of IP. The foundational work on ionizable lipid pKa optimisation, LNP structural design, and microfluidic synthesis methods is particularly well documented in both patent and literature form, creating a dense prior art environment.
Prior Art Relevance
For applicants filing new patents in ionizable lipid chemistry, LNP formulation, mRNA delivery optimisation, or extrahepatic targeting, the Cullis literature constitutes well-established prior art that patent offices globally will identify during examination. The 2012 Alnylam/UBC paper on pKa optimisation (997 citations), the 2018 LNP morphology paper (525 citations), and the 2019 Onpattro clinical translation paper (1,319 citations) are among the most referenced works in this field and will figure prominently in any novelty or inventive step analysis.
Pieter R. Cullis — Patent & Research FAQs
Analyse Pieter R. Cullis's Full IP Landscape
Search 208M+ patents and papers to map the complete LNP patent landscape, track emerging filings in extrahepatic delivery, and conduct FTO analysis across the Cullis-associated portfolio — all in PatSnap Eureka IP.
References & External Sources
- 1. Cullis PR et al. "The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs." Nature Materials, 2019. View on PatSnap Eureka
- 2. Semple SC, Akinc A, Chen J, et al. "Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo." Nature Biotechnology, 2012. View on PatSnap Eureka
- 3. Kulkarni JA et al. "On the Formation and Morphology of Lipid Nanoparticles Containing Ionizable Cationic Lipids and siRNA." ACS Nano, 2018. View on PatSnap Eureka
- 4. Cullis PR, Hope MJ. "Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics." Molecular Therapy, 2019. View on PatSnap Eureka
- 5. Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA LNPs, 2013. View on PatSnap Eureka
- 6. USPTO Patent Database: www.uspto.gov — US patent filings associated with UBC and Acuitas Therapeutics
- 7. EPO Espacenet: worldwide.espacenet.com — European patent filings in LNP drug delivery
- 8. WIPO PatentScope: patentscope.wipo.int — PCT applications in nucleic acid delivery technology
PatSnap Eureka searches 208M+ patents and papers to answer instantly.